Skip to search formSkip to main contentSkip to account menu

Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05

Known as: FBTA05 
A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. FBTA05 contains two antigen-recognition sites: one for human… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds
Abstract Monoclonal antibodies (mAbs) are a swiftly growing class of targeted therapeutics for malignancies. After their first… 
Review
2015
Review
2015
Advances in therapies for non-Hodgkin lymphoma in children.
  • R. KobosW. Terry
  • Hematology. American Society of Hematology…
  • 2015
  • Corpus ID: 27002426
Pediatric patients with newly diagnosed, non-Hodgkin Lymphoma (NHL) have an excellent overall survival. However, therapy regimens… 
2013
2013
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell…
Patients with B cell malignancies refractory to allogeneic stem cell transplantation (SCT) can be treated by subsequent… 
2011
2011
Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism
Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)